Sentinel Lymph Node Biopsy in Nonmelanoma Skin Cancer Patients
The management of lymph nodes in nonmelanoma skin cancer patients is currently still debated. Merkel cell carcinoma (MCC), squamous cell carcinoma (SCC), pigmented epithelioid melanocytoma (PEM), and other rare skin neoplasms have a well-known risk to spread to regional lymph nodes. The use of sent...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Journal of Skin Cancer |
| Online Access: | http://dx.doi.org/10.1155/2013/267474 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565160207712256 |
|---|---|
| author | Marie-Laure Matthey-Giè Ariane Boubaker Igor Letovanec Nicolas Demartines Maurice Matter |
| author_facet | Marie-Laure Matthey-Giè Ariane Boubaker Igor Letovanec Nicolas Demartines Maurice Matter |
| author_sort | Marie-Laure Matthey-Giè |
| collection | DOAJ |
| description | The management of lymph nodes in nonmelanoma skin cancer patients is currently still debated.
Merkel cell carcinoma (MCC), squamous cell carcinoma (SCC), pigmented epithelioid melanocytoma (PEM), and other rare skin neoplasms have a well-known risk to spread to regional lymph nodes. The use of sentinel lymph node biopsy (SLNB) could be a promising procedure to assess this risk in clinically N0 patients. Metastatic SNs have been observed in 4.5–28% SCC (according to risk factors), in 9–42% MCC, and in 14–57% PEM. We observed overall 30.8% positive SNs in 13 consecutive patients operated for high-risk nonmelanoma skin cancer between 2002 and 2011 in our institution. These high rates support recommendation to implement SLNB for nonmelanoma skin cancer especially for SCC patients. Completion lymph node dissection following positive SNs is also a matter of discussion especially in PEM. It must be remembered that a definitive survival benefit of SLNB in melanoma patients has not been proven yet. However, because of its low morbidity when compared to empiric elective lymph node dissection or radiation therapy of lymphatic basins, SLNB has allowed sparing a lot of morbidity and could therefore be used in nonmelanoma skin cancer patients, even though a significant impact on survival has not been demonstrated. |
| format | Article |
| id | doaj-art-4408d3c7eff646cf97335d3baacc3455 |
| institution | Kabale University |
| issn | 2090-2905 2090-2913 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Skin Cancer |
| spelling | doaj-art-4408d3c7eff646cf97335d3baacc34552025-02-03T01:09:05ZengWileyJournal of Skin Cancer2090-29052090-29132013-01-01201310.1155/2013/267474267474Sentinel Lymph Node Biopsy in Nonmelanoma Skin Cancer PatientsMarie-Laure Matthey-Giè0Ariane Boubaker1Igor Letovanec2Nicolas Demartines3Maurice Matter4Department of Visceral Surgery, University Hospital CHUV, Lausanne, SwitzerlandDepartment of Nuclear Medicine, University Hospital CHUV, Lausanne, SwitzerlandDepartment of Pathology, University Hospital CHUV, Lausanne, SwitzerlandDepartment of Visceral Surgery, University Hospital CHUV, Lausanne, SwitzerlandDepartment of Visceral Surgery, University Hospital CHUV, Lausanne, SwitzerlandThe management of lymph nodes in nonmelanoma skin cancer patients is currently still debated. Merkel cell carcinoma (MCC), squamous cell carcinoma (SCC), pigmented epithelioid melanocytoma (PEM), and other rare skin neoplasms have a well-known risk to spread to regional lymph nodes. The use of sentinel lymph node biopsy (SLNB) could be a promising procedure to assess this risk in clinically N0 patients. Metastatic SNs have been observed in 4.5–28% SCC (according to risk factors), in 9–42% MCC, and in 14–57% PEM. We observed overall 30.8% positive SNs in 13 consecutive patients operated for high-risk nonmelanoma skin cancer between 2002 and 2011 in our institution. These high rates support recommendation to implement SLNB for nonmelanoma skin cancer especially for SCC patients. Completion lymph node dissection following positive SNs is also a matter of discussion especially in PEM. It must be remembered that a definitive survival benefit of SLNB in melanoma patients has not been proven yet. However, because of its low morbidity when compared to empiric elective lymph node dissection or radiation therapy of lymphatic basins, SLNB has allowed sparing a lot of morbidity and could therefore be used in nonmelanoma skin cancer patients, even though a significant impact on survival has not been demonstrated.http://dx.doi.org/10.1155/2013/267474 |
| spellingShingle | Marie-Laure Matthey-Giè Ariane Boubaker Igor Letovanec Nicolas Demartines Maurice Matter Sentinel Lymph Node Biopsy in Nonmelanoma Skin Cancer Patients Journal of Skin Cancer |
| title | Sentinel Lymph Node Biopsy in Nonmelanoma Skin Cancer Patients |
| title_full | Sentinel Lymph Node Biopsy in Nonmelanoma Skin Cancer Patients |
| title_fullStr | Sentinel Lymph Node Biopsy in Nonmelanoma Skin Cancer Patients |
| title_full_unstemmed | Sentinel Lymph Node Biopsy in Nonmelanoma Skin Cancer Patients |
| title_short | Sentinel Lymph Node Biopsy in Nonmelanoma Skin Cancer Patients |
| title_sort | sentinel lymph node biopsy in nonmelanoma skin cancer patients |
| url | http://dx.doi.org/10.1155/2013/267474 |
| work_keys_str_mv | AT marielauremattheygie sentinellymphnodebiopsyinnonmelanomaskincancerpatients AT arianeboubaker sentinellymphnodebiopsyinnonmelanomaskincancerpatients AT igorletovanec sentinellymphnodebiopsyinnonmelanomaskincancerpatients AT nicolasdemartines sentinellymphnodebiopsyinnonmelanomaskincancerpatients AT mauricematter sentinellymphnodebiopsyinnonmelanomaskincancerpatients |